Dendritic Cell News and Research

Latest Dendritic Cell News and Research

MDA5 molecule plays a critical role in fighting viral infections

Researchers have identified the primary player of the biochemical bugle call that musters the body's defenders against viral infection.

14 Jun 2012

Preliminary results from Incyte’s INCB024360 Phase I trial on solid tumors

Incyte Corporation presented preliminary results today from the ongoing Phase I clinical trial for its oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB024360, at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

5 Jun 2012

ImmunoCellular to present new data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., announced today it will present new data from the previously completed Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

1 Jun 2012

Breast cancer vaccine that elicits powerful immune response also improves recurrence rates

A breast cancer vaccine already shown to elicit a powerful immune response in women with varying levels of HER2 expression has the ability to improve recurrence rates and is well tolerated in an adjuvant setting, according to new research from a clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

18 May 2012

Study shows how PCBs could add to autism risk

New research from UC Davis and Washington State University shows that PCBs, or polychlorinated biphenyls, launch a cellular chain of events that leads to an overabundance of dendrites - the filament-like projections that conduct electrochemical signals between neurons - and disrupts normal patterns of neuronal connections in the brain.

26 Apr 2012

Researchers discover how dendritic cells exchange information to amplify immune response

Using a new fluorescent biosensor they developed, researchers at Carnegie Mellon University have discovered how a key set of immune cells exchange information during their coordinated assault on invading pathogens.

24 Apr 2012

Agennix, DSM sign new contract to manufacture talactoferrin for NSCLC

DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V., and Agennix AG have signed a new contract under which DSM will continue to manufacture talactoferrin for Agennix at commercial levels.

13 Mar 2012

Celldex fourth quarter net loss increases to $12.7 million

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2011.

8 Mar 2012

Combination of implanted DCs and EBRT effective in creating sarcoma tumor immune response

A team of 18 researchers at Moffitt Cancer Center in Tampa, Fla., have found that treating high-risk, soft tissue sarcoma patients with a combination of implanted dendritic cells (immune system cells) and fractionated external beam radiation (EBRT) provided more than 50 percent of their trial patients with tumor-specific immune responses lasting from 11 to 42 weeks.

2 Mar 2012

University of Pennsylvania, IMUC enter license agreement for dendritic-cell production method

ImmunoCellular Therapeutics today announced that it has entered into an agreement with the University of Pennsylvania under which University of Pennsylvania has granted the Company an exclusive, worldwide license for a patent pending technology for the production of high-activity dendritic cells.

21 Feb 2012

Starving HIV virus could be the basis for future therapy: Study

In a medical breakthrough researchers at NYU Langone Medical Center and colleagues have shown how some cells in the body can repel attacks from HIV by starving the virus of the building blocks of life.

13 Feb 2012

Study investigates how cytokine IFN-λ release is regulated

In new research appearing in this month's issue of the journal Nature Immunology, Roy Curtiss, director of the Center for Infectious Diseases and Vaccinology at the Biodesign Institute at Arizona State University, along with international collaborators, investigates the coordination of a particular type of immune response, involving the release of of IFN-λ- a cell-signaling protein molecule known as a cytokine.

10 Feb 2012

Multiple DNA repair defect in monocytes

Scientists working with Professor Bernd Kaina of the Institute of Toxicology at the Medical Center of Johannes Gutenberg University Mainz have demonstrated for the first time that certain cells circulating in human blood - so-called monocytes - are extremely sensitive to reactive oxygen species (ROS).

3 Feb 2012

ImmunoCellular receives U.S. patent allowance for cancer stem cell treatment

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to the Company's method of treating glioblastoma multiforme (GBM) in a patient by targeting cancer stem cells.

2 Feb 2012

IMUC president to present at Immunotherapeutics Partnering and Deal Making Conference

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, today announced that its president and CEO, Manish Singh Ph.D., will be presenting at the Immunotherapeutics Partnering and Deal Making Conference, which will take place in San Diego, California on January 30-31, 2012.

31 Jan 2012

Anti-HER2 dendritic cell vaccine shows promise against DCIS

Researchers at the Perelman School of Medicine at the University of Pennsylvania report that a short course of vaccination with an anti-HER2 dendritic cell vaccine made partly from the patient's own cells triggers a complete tumor eradication in nearly 20 percent of women with ductal carcinoma in situ (DCIS), an early breast cancer.

31 Jan 2012

ImmunoCellular initiates enrollment in ICT-107 Phase II trial for GBM in 23 centers

ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, provided an update today on clinical trial site activity and patient enrollment for its Phase II clinical trial of ICT-107, the Company's dendritic cell based cancer vaccine candidate targeting multiple tumor antigens for the treatment of glioblastoma multiforme.

24 Jan 2012

Scientists seek to prove beta oscillations of the cortex

Before she could seek to convince the world that her computer model of a key brain circuit explains a fundamental, 80-year-old mystery of neuroscience with potential relevance to Parkinson's disease, Stephanie Jones sought to convince Christopher Moore.

29 Nov 2011

Immunicum receives Swedish approval to commence first clinical trial of patented cancer vaccine

Immunicum, which is developing cancer vaccines, has received approval from the Swedish Medical Products Agency to start its first clinical trial. The study will be conducted on kidney cancer patients at the University Hospital in Uppsala. At the same time, the company secures substantial financing to complete the clinical trial.

25 Nov 2011

Dendritic cells play a novel protective role in pancreas

NYU Langone Medical Center researchers have discovered the novel protective role dendritic cells play in the pancreas. The new study, published in the November issue of journal Gastroenterology, shows dendritic cells can safeguard the pancreas against acute pancreatitis, a sudden dangerous swelling and inflammation of the pancreas gland.

23 Nov 2011